argenx SE 2023 AR2
The report highlights argenx SE's transition to a commercial-stage global biopharma company in 2023, generating $1.2 billion in product net sales from VYVGART and VYVGART SC. The company advanced its immunology pipeline, achieving proof-of-concept for empasiprubart in multifocal motor neuropathy and submitting a supplemental Biologics License Application for subcutaneous efgartigimod in chronic inflammatory demyelinating polyneuropathy. Additionally, argenx expanded its workforce to 1,148 employees and progressed its corporate sustainability reporting readiness under the European Union's Corporate Sustainability Reporting Directive.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2023
Type: AR2
Pages: 396
Back to company
argenx SE
Annual Report
The report highlights argenx SE's transition to a commercial-stage global biopharma company in 2023, generating $1.2 billion in product net sales from VYVGART and VYVGART SC. The company advanced its immunology pipeline, achieving proof-of-concept for empasiprubart in multifocal motor neuropathy and submitting a supplemental Biologics License Application for subcutaneous efgartigimod in chronic inflammatory demyelinating polyneuropathy. Additionally, argenx expanded its workforce to 1,148 employees and progressed its corporate sustainability reporting readiness under the European Union's Corporate Sustainability Reporting Directive.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees